Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof

Patent metadata

Field	Value
Publication number	US-9561264-B2
Application number	US-201313938938-A
Country	US
Kind code	B2
Filing date	Jul 10, 2013
Priority date	Jun 5, 2000
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.

First claim

What is claimed is:

1. An isolated monoclonal antibody specific for a 7p15-21 P-glycoprotein, wherein the 7p15-21 P-glycoprotein comprises SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and wherein the antibody selectively binds to SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

2. The isolated monoclonal antibody of claim 1 , wherein the antibody is in cell toxin-conjugated form and is conjugated to a toxin.

3. A method of treating a subject having cancer, comprising administering to the subject an isolated monoclonal antibody of claim 1 , wherein the subject has a cancer that expresses 7p15-21 P-glycoprotein and wherein the subject is treated with a cancer chemotherapy.

4. A method comprising administering a tumor vaccine comprising a 7p15-21 P-glycoprotein to a subject for the treatment of cancer, wherein the subject has a cancer that expresses 7p15-21 P-glycoprotein.

5. The method of claim 4 , wherein the 7p15-21 P-glycoprotein is a protein consisting essentially of an amino acid sequence selected from the group consisting of: SEQ ID NO:1; SEQ ID NO:2; and SEQ ID NO:3.

Assignees

• Brigham & Womens Hospital Inc

Inventors

• Frank Markus H
• Sayegh Mohamed H

Classifications

• A61P37/02

  Immunomodulators · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title